



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

December 2, 2020

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Sub.: Detailed statement of cash flow for the period ended September 30, 2020

- Ref.: 1. Outcome of the meeting of the Board of Directors of Novartis India Limited (“the Company”) held on November 5, 2020**
2. Email dated November 27, 2020 received from BSE listing department requesting to submit detailed statement of cash flow
3. Scrip Code: 500672

Dear Sir/ Madam,

Apropos the subject matter quoted above and in continuation to our previous disclosure dated November 5, 2020 and as per the e-mail received from BSE Listing center on November 27, 2020, please find enclosed herewith detailed statement of cash flow for the period ended September 30, 2020.

Kindly take note of the above additional information in your records.

Thanking you

Yours sincerely,

For **Novartis India Limited**

Trivikram Guda
Company Secretary &
Compliance Officer

Novartis India Limited
Statement of Cash Flows for the period ended 30th September, 2020

	Period ended 30th September 2020 in ₹ million
A. Cash flow from operating activities	
Profit before tax	174.6
Adjustments for -	
Depreciation and Amortisation Expense	61.6
Share Based Payments	5.3
Interest Income	(111.6)
Unwinding of discount on security deposits	(1.2)
Finance Costs	33.4
Loss/(Gain) on sale of Property, Plant and Equipment (Net)	1.2
Unrealised Loss/(Gain) on Foreign currency translations (Net)	(0.2)
Provisions no Longer Required Written-Back	(12.8)
Provision for Doubtful Debts, Advances and Deposits	0.8
Operating (Loss)/ profit before working capital changes	151.1
Change in operating assets and liabilities	
Decrease/(Increase) in Trade Receivables	124.5
Decrease/(Increase) in Inventories	(56.3)
Decrease in Trade Payables	(174.7)
Increase in Financial Assets	(109.6)
(Increase)/Decrease in Other Non-Current Assets	(1.5)
Increase in Other Current Assets	(77.0)
Increase/(Decrease) in Provisions	16.6
Increase/(Decrease) in Other Current Liabilities	(35.6)
Increase/(Decrease) in Financial Liabilities	(135.9)
Cash generated from/(used in) operations	(298.3)
Income Tax Paid (Net)	(196.1)
Net cash generated / (used) in operating activities	(494.4)
B. Cash flow from investing activities	
Payments for Property, Plant and Equipment	(1.7)
Interest received	130.2
Fixed deposits matured (net)	218.0
Net cash from investing activities	346.5
C. Cash flow from financing activities	
Lease payments	
- Principal	(24.9)
- Interest	(33.0)
Dividends paid	(226.1)
Tax on Dividend	(20.8)
Net cash used in financing activities	(304.8)
Net Increase / (Decrease) in Cash and Cash Equivalents	(452.7)
Cash and Cash Equivalents - At the beginning of the year	791.2
Cash and Cash Equivalents - At the end of the year	338.5

Note:

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7 Statement of Cash Flows.

For and on behalf of the Board

**Sd/-
Sanjay Murdeshwar**

Vice Chairman & Managing Director
DIN:01481811

Mumbai, December 2, 2020